Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

eZono appoints Cox CEO

This article was originally published in Clinica

Executive Summary

German tablet ultrasound system developer eZono has made ultrasound industry veteran Graham Cox CEO, effective 1 June. He will succeed co-founder and acting CEO Allan Dunbar, who will stay with the company as chief commercial officer. Mr Cox previously worked for another ultrasound specialist, SonoSite, for 13 years, most recently as vice-president, worldwide sales and distribution. SonoSite was acquired by Fujifilm in 2011 (www.clinica.co.uk, 15 December 2011). Before this, he had senior positions at ATL Ultrasound (which Philips acquired in 1998, www.clinica.co.uk, 3 August 1998) and Acuson (which Siemens acquired in 2000, www.clinica.co.uk, 2 October 2000). Privately-held eZono’s first-generation product, the eZono 3000, is CE marked for sale in Europe and gained US FDA 510(k) clearance in July 2011. The Jena-based firm’s ultrasound devices are aimed at the point-of-care market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel